NCT05582538
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05582538
Title Ceralasertib Followed by Durvalumab and Nab-paclitaxel Combination in mTNBC Patients (ATRiBRAVE)
Acronym ATRiBRAVE
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors IFOM, The FIRC Institute of Molecular Oncology
Indications
Therapies
Age Groups: senior | adult
Covered Countries ITA

Facility Status City State Zip Country Details
Azienda Ospedaliero Universitaria Maggiore della Carità RECRUITING Novara Novara Italy Details
ASST Papa Giovanni XXIII RECRUITING Bergamo 24127 Italy Details
Istituto Nazionale dei Tumori IRCCS RECRUITING Milan Italy Details
IRCCS Istituto Nazionale Tumori "Fondazione Giovanni Pascale" RECRUITING Napoli 80131 Italy Details
Istituto Oncologico Veneto IRCCS RECRUITING Padua Italy Details
Azienda U.S.L. - IRCCS di Reggio Emilia RECRUITING Reggio Emilia Italy Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field